Answers are grounded in this paper and cite their sources.
Narrative review summarizes regenerative therapies restoring melanocytes and their microenvironment in vitiligo, indicating therapeutic promise.
Background Vitiligo is the most common acquired depigmentary disorder, affecting approximately 0.5%–2% of the global population. Although traditionally considered an autoimmune disease leading to melanocyte destruction, accumulating evidence indicates a multifactorial pathogenesis involving oxidative stress, immune dysregulation, metabolic abnormalities, and impaired regenerative capacity of melanocyte stem cells within the follicular niche. Conventional medical therapies often fail to achieve stable and durable repigmentation in resistant or long‐standing lesions. Regenerative medicine has therefore emerged as a promising therapeutic paradigm aimed at restoring melanocyte populations and re‐establishing a supportive cutaneous microenvironment. Methods A narrative review of the literature was conducted to summarize current regenerative approaches for vitiligo. The review focuses on cellular and non‐cellular replacement therapies, microenvironment‐modulating strategies, and hybrid multimodal interventions, with emphasis on the rationale and the clinical outcomes reported in recent studies. Results Regenerative therapies can be broadly categorized into cell‐based and cell‐free approaches. Cell‐based modalities include established modalities like cultured melanocyte transplantation, non‐cultured epidermal cell suspension (NCES), follicular melanocyte transplantation, and emerging stem cell‐based therapies. Cell‐free strategies aim to restore the melanocyte niche through both established and experimental modalities like platelet‐rich plasma, mesenchymal stromal stem cell‐derived products, exosomes, and cytokine‐modulating agents, including Janus kinase inhibitors. However, variability in treatment protocols and limited high‐quality randomized controlled trials remain important limitations. Conclusion Regenerative medicine represents a promising therapeutic frontier in vitiligo by integrating melanocyte replacement, microenvironment restoration, and immune modulation. Advances in stem cell biology, bioengineering, and precision dermatology may further refine these strategies and enable more durable repigmentation outcomes.
No takes yet. Share an insight, caveat, or question.
Oberoi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: